| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/07/2022 | 433.33% | Piper Sandler | $10 → $8 | Maintains | Overweight |
| 04/26/2021 | 633.33% | JP Morgan | → $11 | Initiates Coverage On | → Underweight |
| 04/26/2021 | 1233.33% | B of A Securities | → $20 | Initiates Coverage On | → Buy |
| 04/26/2021 | 1700% | Chardan Capital | → $27 | Initiates Coverage On | → Buy |
| 04/26/2021 | 1566.67% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 04/26/2021 | 1433.33% | Oppenheimer | → $23 | Initiates Coverage On | → Outperform |
What is the target price for Achilles Therapeutics (ACHL)?
The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Piper Sandler on December 7, 2022. The analyst firm set a price target for $8.00 expecting ACHL to rise to within 12 months (a possible 433.33% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Achilles Therapeutics (ACHL)?
The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Piper Sandler, and Achilles Therapeutics maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Achilles Therapeutics (ACHL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.
Is the Analyst Rating Achilles Therapeutics (ACHL) correct?
While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a maintained with a price target of $10.00 to $8.00. The current price Achilles Therapeutics (ACHL) is trading at is $1.50, which is out of the analyst's predicted range.